{
    "title": "112_hr3209",
    "content": "The \"Premarket Predictability Act of 2011\" is the short title of this Act. It involves tracking and reviewing applications for investigational device exemptions. Section 520(g) of the Federal Food, Drug, and Cosmetic Act is amended to require the Secretary to assign a tracking number to a device upon submission of an exemption application, device classification request, or report under section 510(k). The tracking number is used to record interactions between the Secretary and the applicant regarding the device. The Secretary assigns a tracking number to a device upon submission of an exemption application, device classification request, or report under section 510(k). The application process includes various steps such as submission, approval, requests for additional information, deficiency letters, applicant responses, written submissions to the FDA, and other relevant matters as determined by the Secretary. Additionally, a reviewer with prior experience in the device type or relevant expertise is assigned to review the application. SEC. 3. OTHER RULES RELATING TO INVESTIGATIONAL DEVICE EXEMPTIONS. Section 520(g) of the Federal Food, Drug, and Cosmetic Act is amended to require the Secretary to evaluate whether investigational studies can be conducted ethically and with reasonable risk. The amendment also prohibits disapproval of applications based on not meeting certain requirements. The amendment to Section 520(g) of the Federal Food, Drug, and Cosmetic Act requires the Secretary to evaluate investigational studies for ethical conduct and reasonable risk. It also prohibits disapproval of applications based on certain requirements. Additionally, the amendment allows for the submission of investigational plans for review before application submission. The Secretary must meet with the applicant within 30 days of receiving a request to reach an agreement on the investigational plan. The request should include detailed descriptions of the device, proposed conditions of use, expected performance, and a plan for determining safety and effectiveness. If the Secretary fails to meet the applicant within the specified timeframe, certain actions may be taken. The proposed plan submitted within 30 days of a request will be considered the agreement between the Secretary and the applicant, with limited changes allowed. Additionally, any new scientific issues arising after the agreement must be addressed. SEC. 4. CLARIFICATION OF LEAST BURDENSOME STANDARD. In amending the Federal Food, Drug, and Cosmetic Act, the Secretary is directed to streamline the process for device effectiveness evaluation by avoiding irrelevant information, exploring alternative approaches, reducing review times, and considering pre-clinical data for approval. The amendment to the Federal Food, Drug, and Cosmetic Act focuses on streamlining the device effectiveness evaluation process by considering alternatives to clinical trials, using surrogate endpoints, and ensuring that only relevant information is requested for substantial equivalence determination. The amendment to the Federal Food, Drug, and Cosmetic Act aims to streamline the device evaluation process by considering alternative approaches to evaluating substantial equivalence, reducing time and cost, and using reasonable mechanisms to expedite regulatory decisions. SEC. 5. AGENCY DOCUMENTATION AND REVIEW OF SIGNIFICANT DECISIONS. Chapter V of the Federal Food, Drug, and Cosmetic Act is amended to include a new section, SEC. 517A, focusing on agency documentation and review of significant decisions regarding devices. The Secretary must document the rationale for significant decisions made by the Center for Devices and Radiological Health. This documentation should include controversies, differences of opinion, and their resolution. Upon request, the Secretary must provide this documentation to the relevant person. Additionally, individuals have the right to appeal to the center director within 30 days of a significant decision. After a significant decision, individuals can appeal to the Center Director of the Center for Devices and Radiological Health within 30 days. The appeal must be in writing and state the decision being appealed and the grounds for appeal. The Center Director may establish necessary procedures for the appeal and provide for at least one meeting upon request. The Center Director must hold a meeting within 45 days of the appeal filing to discuss the decision and possible resolutions. A final decision must be issued within 90 days. Appeals can be made to the commissioner within 30 days of receiving the Center Director's decision. The Commissioner must issue a final decision on any appeal within 30 days of filing, and an annual public report must be issued. The annual report must include the number of appeals, time taken for final decisions, appeals to the Commissioner, and appeals without a final decision within 30 days. The Secretary has the authority to establish appeal procedures and timelines. The Secretary may establish appeal procedures and timelines for appeals, with limitations on altering requirements or timelines specified in the paragraphs. SEC. 6. TRANSPARENCY IN CLEARANCE PROCESS. The Secretary shall publish detailed decision summaries for each device clearance under section 510(k) of the Federal Food, Drug, and Cosmetic Act. This requirement applies to clearances after the enactment of this Act."
}